First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Novel Approaches in Prostate Cancer Treatment

Peer Exchange

PROfound: Olaparib for HRR+ mCRPC

ADT and Its Consequences in the Treatment of Prostate Cancer

Combination Therapy for Localized Prostate Cancer

Optimal ADT for Patients With Prostate Cancer and CV History

Active Surveillance and Prognostic Value of Prostate Biopsy

Early Salvage Radiotherapy for Early Prostate Cancer

Nonmetastatic Castration-Resistant Prostate Cancer

ARAMIS: Safety and Efficacy of Darolutamide in nmCRPC

QOL in Nonmetastatic Castration-Resistant Prostate Cancer

Prostate Cancer: PSA-DT and Initiating AR-Targeted Therapy

Clinical Phenotypes of Prostate Cancer and Prognostic Factors

STAMPEDE: Docetaxel for Hormone-Naive Prostate Cancer

Prostate Cancer: Characterize Biologies, Integrate Therapies

Triplet vs Doublet Therapy for mCSPC

Role of Biomarkers in Metastatic Prostate Cancer

CARD: Sequencing Therapies in Metastatic Prostate Cancer

Optimal Timing for Radium-223 With AR-Targeted Therapy

Final Thoughts on Evolving Treatment of Prostate Cancer